|
Study
(author/year/microspheres type/reference) | PVTT
population/total population | 6-month survival (%) | Disease Control rate at
months (%) | Median OS
(months) | Median PFS
(months) |
|
|
Salem et al., 2004: glass [15] | | 53 | — | 7.1
(4.1–13.9) | — |
|
Woodall et al., 2009: glass [18] | | — | — | 3.2 | — |
|
Kulik et al., 2008: glass [14] | | — | — | Branch
PVTT: 9.9 (7.1–15.7)
Main
PVTT: 4.4 (2.9–7.4) | — |
|
Tsai et al., 2010: glass and resin [17] |
15 evaluable | — | 2-3 months: 58 (RECIST) | 7.0 | — |
Iñarrairaegui et al., 2010: resin
[13] | | 64 | 2 months: 66.7 and
6 months: 50 (RECIST) | 10.0
(6.6–13.3) | — |
Hilgard et al., 2010: glass
[12] | | 65
(95% CI 46–92%) | 3 months: 90 (RECIST) 94 (EASL) | 10.0 (6.0–∞) | 8.0 (5.9–∞) |
Salem et al., 2010: glass
[16]
|
(35 Child A and 57 Child B) | — | 2-3 months: 50 Child A
and 32 Child B (EASL) | 10.4 (7.2–16.6) Child A
5.6 (4.5–6.7) Child B | 5.6 (2.3–7.6) Child A
5.9 (4.2–7.9) Child B |
Sangro et al., 2011: resin
[24] |
(branch + main) | — | 3 months: 88.9% (EASL) | 10.2
(7.7–11.8) | — |
Mazzaferro et al., 2012: glass
[25]
|
(branch + main) | — | 3 months: 74.3 (EASL) | 13.0
(9.0–17.0) | 7.0
(6.0–12.0) |
|
